Business Context and Reporting Period
Company: Alcon, Inc.
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Three and nine months ended September 30, 2003
Filing Date: October 30, 2003
Business Overview: Alcon operates globally in the ophthalmic market through two segments: Alcon United States and Alcon International. The company markets pharmaceuticals, surgical equipment/devices, and consumer eye care products.
Key Financial Metrics
| Financial Metric (in millions) | 3 Months Ended Sept 30, 2003 | 9 Months Ended Sept 30, 2003 | 9 Months Ended Sept 30, 2002 |
|---|---|---|---|
| Sales | $822.7 | $2,555.2 | $2,259.9 |
| Gross Profit | $594.4 | $1,806.5 | $1,600.5 |
| Gross Margin | 72.2% | 70.7% | 70.8% |
| Operating Income | $224.6 | $679.9 | $584.4 |
| Net Earnings | $153.1 | $461.5 | $381.9 |
| Diluted EPS | $0.49 | $1.49 | $1.27 |
| Cash from Operations (9mo) | N/A | $669.8 | $526.3 |
| Cash & Equivalents (Sept 30, 2003) | $1,195.1 | ||
| Total Debt (Sept 30, 2003) | $1,714.2 | ||
| Net Debt (Sept 30, 2003) | $519.1 |
Material Changes vs. Prior Period
- Revenue Growth: Global sales increased 10.6% in Q3 2003 and 13.1% for the nine-month period compared to 2002. Growth was driven by pharmaceuticals (11.6% Q3, 19.8% 9mo) and surgical products (10.5% Q3, 10.1% 9mo). Currency fluctuations (stronger Euro) contributed approximately 3.0% to Q3 growth and 3.7% to 9-month growth.
- Profitability: Net earnings rose 22.4% in Q3 and 20.8% for the nine months. Operating income margins improved to 27.3% in Q3 (from 26.3% in 2002) and 26.6% for the nine months (from 25.9% in 2002).
- Product Performance:
- Pharmaceuticals: Strong growth in glaucoma products (Travatan) and infection products (Vigamox, Ciprodex Otic). Otic products declined 1.7% in Q3 due to a strong prior-year quarter and wholesaler inventory reductions.
- Surgical: Intraocular Lenses (AcrySof) and cataract/vitreoretinal products drove growth. Refractive products declined 6.7% in Q3 due to economic conditions and low demand for laser equipment.
- Consumer: Artificial tears (Systane) and contact lens disinfectants (Opti-Free) showed solid growth.
- Debt Reduction: Net debt decreased by $389.7 million during the first nine months of 2003, primarily due to strong operating cash flow used to reduce short-term borrowings and pay dividends.
Guidance, Outlook, and Risks
- Outlook: Management expects year-over-year improvement for the full year 2003 due to operating leverage gained from global infrastructure. The company anticipates meeting liquidity needs through operating cash flows and existing credit facilities.
- Key Risks:
- Currency Risk: Significant exposure to foreign exchange rates; a 10% appreciation of foreign currencies against the USD could decrease pre-tax earnings by approximately $3.7 million (hedged).
- Interest Rate Risk: Majority of debt is short-term floating rate; a 1% increase in rates would decrease pre-tax earnings by $3.4 million.
- Regulatory & Litigation: Risks related to product recalls, government regulation, reimbursement changes, and ongoing patent/product liability litigation.
- Market Conditions: Dependence on third-party payors and potential supply/manufacturing disruptions.
- Unusual Items: The 2002 comparative period included one-time charges of $22.6 million related to deferred compensation plan changes and estimated interest expense impacts from IPO proceeds timing. Excluding these, 2002 operating income would have been higher.
Investor Verification Checklist
- Constant Currency Growth: Verify organic growth rates excluding the favorable impact of the strong Euro (approx. 7.6% Q3 and 9.4% 9mo constant currency growth).
- Refractive Segment: Monitor the continued decline in refractive product sales and the impact of global economic conditions on elective procedures.
- Debt Structure: Review the concentration of short-term floating-rate debt ($1.6 billion) and the reliance on Nestlé guarantees for commercial paper facilities.
- Product Launches: Assess the market penetration and revenue contribution of new products: Travatan, Vigamox, Ciprodex Otic, AcrySof Natural, Infiniti, and LADARWave.
- Inventory Levels: Note the increase in inventories to $448.6 million (from $412.3 million) and potential obsolescence risks.